Fig 4.
a. Inhibition of HIV growth in vitro by vaginal fluids of TFV/LNG IVR users (continuous and cyclic dosing regimens combined) at baseline and 1 and 3 months after use. b. Correlation between [TFV] and Anti-HIV activity in CVF TFV/LNG IVRs.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.